Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/12 21:54:45」(JST)

wiki en

Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.^[1]

Mechanism

It is classified as a purine analog, which is a type of antimetabolite.

It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA.^[2]

Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.

Uses

Pentostatin is used to treat hairy cell leukemia.^[3] It is given by intravenous infusion once every two weeks for three to six months.

Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease.^[4]

Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.

References

^ Kay NE, Geyer SM, Call TG, et al. (January 2007). "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia". Blood 109 (2): 405–11. doi:10.1182/blood-2006-07-033274. PMC 1785105. PMID 17008537.
^ Sauter C, Lamanna N, Weiss MA (September 2008). "Pentostatin in chronic lymphocytic leukemia". Expert Opin Drug Metab Toxicol 4 (9): 1217–22. doi:10.1517/17425255.4.9.1217. PMID 18721115.
^ Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". Cancer Invest. 26 (8): 860–5. doi:10.1080/07357900801965034. PMID 18798068.
^ Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB (April 2005). "Pentostatin in steroid-refractory acute graft-versus-host disease". J Clin Onc 23 (12): 2661–8. doi:10.1200/JCO.2005.06.130. PMID 15837980.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 症候性または進行した慢性リンパ性白血病に対する初期治療の選択 selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia
2. T細胞性前リンパ性白血病の治療 treatment of t cell prolymphocytic leukemia
3. 有毛細胞白血病の治療 treatment of hairy cell leukemia
4. 急性移植片対宿主病の治療：臨床試験 treatment of acute graft versus host disease clinical trials
5. プリンアナログ療法後の自己免疫性合併症 autoimmune complications following purine analog therapy

English Journal

A pediatric case of T-cell prolymphocytic leukemia.

Mitton B1, Coutre S, Willert J, Schlis K, Porteus M, Kharbanda S, Agarwal-Hashmi R.
Pediatric blood & cancer.Pediatr Blood Cancer.2015 Jun;62(6):1061-2. doi: 10.1002/pbc.25336. Epub 2014 Nov 21.
T-cell Prolymphocytic Leukemia (T-PLL) is a rare entity, and to date has never been reported in children. Here, we describe the first pediatric case of T-PLL in a 16-year old male and review his clinical course through treatment. He underwent therapy with alemtuzumab and pentostatin, which was succe
PMID 25417638

Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin.

Reese JA1, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, George JN.
American journal of hematology.Am J Hematol.2015 May;90(5):406-10. doi: 10.1002/ajh.23960. Epub 2015 Feb 25.
Many drugs have been reported to cause thrombotic microangiopathy (TMA), often described as thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS). We recently established criteria to evaluate the evidence for a causal association of a drug with TMA and then we systematically r
PMID 25639727

Altered AMP deaminase activity may extend postmortem glycolysis.

England EM1, Matarneh SK1, Scheffler TL1, Wachet C1, Gerrard DE2.
Meat science.Meat Sci.2015 Apr;102:8-14. doi: 10.1016/j.meatsci.2014.11.009. Epub 2014 Nov 27.
Postmortem energy metabolism drives hydrogen accumulation in muscle and results in a fairly constant ultimate pH. Extended glycolysis results in adverse pork quality and may be possible with greater adenonucleotide availability postmortem. We hypothesized that slowing adenonucleotide removal by redu
PMID 25498483

Japanese Journal

複数の治療法を併用した皮膚型成人Ｔ細胞白血病／リンパ腫の１例

石井千寸,天野正宏,持田耕介 [他],堀川永子,瀬戸山充,久冨木庸子
西日本皮膚科 73(4), 362-367, 2011
… 放射線治療を併用しながらEPOCH療法，CPT-11，pentostatinの投与を行い一時症状の改善が得られたが，初診から21ヵ月で死亡した。 …
NAID 130004831807

急性呼吸困難を発症した難治性 hairy cell leukemia-Japanese variant に rituximab が著効した症例

牧田雅典,中村恒仁,河野厚
臨床血液 = The Japanese Journal of Clinical Hematology 46(11), 1196-1201, 2005-11-30
… 血小板減少が進行し2002年6月よりpentostatinを開始されるが反応なく徐々にHCL細胞が増加するためIFN-α, cladribineの投与を施行されるが共に無効であった。 …
NAID 10016878426

維持透析中の慢性型成人T細胞白血病患者に対する pentostatin 治療

有馬靖佳,杉山正敏
臨床血液 = The Japanese Journal of Clinical Hematology 46(11), 1191-1195, 2005-11-30
… Cyclophosphamide, etoposideを投与されたが無効であったため，十分な説明と同意の上pentostatinが投与された。 … Pentostatinは腎不全の患者には投与禁忌であるが，患者が慢性透析中で薬剤濃度の推移を予測・測定しながらであれば，安全に投与しかつ良好な効果が期待し得ると思われ報告した。 …
NAID 10016878418

Related Pictures

Nipent - Pentostatin lijkt effectief bij verschillende vormen van bloedkanker cancer chemotherapy Nipent™ (Pentostatin for Injection) | Pfizerinjectables Nipent intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD Pentostatin (Bedford Laboratories): FDA Package Insert, Page 3 pentostatin intravenous : Uses, Side Effects, Interactions, Pictures, Warnings [Full-Download] Pentostatin Meaning Pentostatin|Irreversible adenosine deaminase inhibitor|CAS# 53910-25-1

★リンクテーブル★

リンク元	「ペントスタチン」「2'-デオキシコホルマイシン」「2-deoxycoformycin」

「ペントスタチン」

Pentostatin
Systematic (IUPAC) name
	(R)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
Clinical data
Trade names	Nipent
AHFS/Drugs.com	monograph
MedlinePlus	a692004
Pregnancy; category	US: D (Evidence of risk); ;
Legal status	CA: ℞-only; UK: Prescription-only (POM); US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	4%
Metabolism	Hepatic, minor
Biological half-life	2.6 to 16 hours, mean 5.7 hours
Identifiers
CAS Registry Number	53910-25-1
ATC code	L01XX08
PubChem	CID: 439693
IUPHAR/BPS	4805
DrugBank	DB00552
ChemSpider	388759
UNII	395575MZO7
KEGG	D00155
ChEMBL	CHEMBL1580
Chemical data
Formula	C11H16N4O4
Molecular mass	268.269 g/mol
	SMILES n1c3c(n(c1)[C@@H]2O[C@@H]([C@@H](O)C2)CO)N\C=N/C[C@H]3O ;
	InChI InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 ; Key:FPVKHBSQESCIEP-JQCXWYLXSA-N ;
(what is this?) (verify)